Differentially expressed glycoproteins in pre- and post-digital rectal examination urine samples for detecting aggressive prostate cancer.

Autor: Wang Y; Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA., Lih TM; Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA., Höti N; Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA., Sokoll LJ; Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA., Chesnut G; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.; Urology Service, Walter Reed National Military Medical Center, Bethesda, Maryland, USA., Petrovics G; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.; Henry Jackson Foundation for the Advancement of Military Medicine (HJF), Bethesda, Maryland, USA., Kohaar I; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.; Henry Jackson Foundation for the Advancement of Military Medicine (HJF), Bethesda, Maryland, USA., Zhang H; Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA.
Jazyk: angličtina
Zdroj: Proteomics [Proteomics] 2023 Apr; Vol. 23 (7-8), pp. e2200023. Date of Electronic Publication: 2023 Jan 26.
DOI: 10.1002/pmic.202200023
Abstrakt: Urinary glycoproteins associated with aggressive prostate cancer (AG-PCa) were previously reported using post-digital rectal examination (DRE) urine specimens. To explore the potential of using pre-DRE urine specimens for detecting AG-PCa, we compared glycoproteins between pre- and post-DRE urine specimens, verified the previously identified post-DRE AG-PCa-associated urinary glycoproteins in pre-DRE urine specimens, and explored potential new glycoproteins for AG-PCa detection in pre-DRE urine specimens. Quantitative glycoproteomic data were acquired for 154 pre-DRE urine specimens from 41 patients with no cancer at biopsy, 48 patients with non-AG-PCa (Gleason score = 6), and 65 patients with AG-PCa (Gleason score 7 or above). Compared to glycopeptides from the post-DRE urine data, humoral immunity-related proteins were enriched in pre-DRE urine samples, whereas cell mediated immune response proteins were enriched in post-DRE urine samples. Analyses of AG-PCa-associated glycoproteins from pre-DRE urine revealed that the three urinary glycoproteins, prostate-specific antigen (PSA), prostatic acid phosphatase (ACPP), and CD97 antigen (CD97) that were previously identified in post-DRE urine samples, were also observed as AG-PCa associated glycoproteins in pre-DRE urine. In addition, we identified three new glycoproteins, fibrillin 1 (FBN1), vitronectin (VTN), and hemicentin 2 (HMCN2), to be potentially associated with AG-PCa in pre-DRE urine specimens. In summary, glycoprotein profiles differ between pre- and post-DRE urine specimens. The identified AG-PCa-associated glycoproteins may be further evaluated in large cohort of pre-DRE urine specimens for detecting clinically significant PCa.
(© 2022 The Authors. Proteomics published by Wiley-VCH GmbH.)
Databáze: MEDLINE
Externí odkaz: